GSK’s HIV drug receives EU advertising and marketing nod .

FILE PHOTO: The GlaxoSmithKline (GSK) brand is seen on high of GSK Asia Home in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Picture

(Reuters) – GlaxoSmithKline stated its specialist HIV firm had obtained advertising and marketing authorization from the European Fee for its drug to deal with superior stage HIV infections in adults and adolescents above the age of 12 and weighing no less than 40 kg.

ViiV Healthcare, which is majority owned by GSK and with Pfizer Inc and Shionogi Ltd as shareholders, received the U.S. Meals and Drug Administration approval for the remedy Dovato in April.

Reporting by Noor Zainab Hussain in Bengaluru; enhancing by Gopakumar Warrier

Our Requirements:The Thomson Reuters Belief Ideas.

Source link.

Tessy Karina


No comments!

There are no comments yet, but you can be first to comment this article.

Leave reply

Your email address will not be published. Required fields are marked *